Soligenix on IDR technology and SGX942
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
List view / Grid view
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
19 August 2015 | By Victoria White
NIAID has provided Soligenix an additional $2.7 million in funding to advance the development of its heat stabilised ricin toxin vaccine, RiVax...
4 August 2015 | By Victoria White
The EC has granted orphan drug designation to Solgenix’s synthetic hypericin (the active ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma...